We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Genflow Biosciences Plc | LSE:GENF | London | Ordinary Share | GB00BP2C3V08 | ORD GBP0.0003 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.90 | 317,567 | 08:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 0.85 | 0.95 | 0.90 | 0.90 | 0.90 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Coml Physical, Biologcl Resh | 320k | -1.59M | -0.0045 | -2.00 | 3.15M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 13:28:01 | O | 39,952 | 0.8625 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 22/5/2025 | 10:51 | UK RNS | Genflow Biosciences PLC AGM Notice |
| 15/5/2025 | 14:30 | ALNC |  EARNINGS AND TRADING: Ondine widens loss as research expenses rise |
| 15/5/2025 | 07:00 | UK RNS | Genflow Biosciences PLC Key SIRT6 Patent Application |
| 12/5/2025 | 10:50 | UK RNS | Genflow Biosciences PLC Holding(s) in Company |
| 09/5/2025 | 18:42 | ALNC | IN BRIEF: Genflow Biosciences says investment a vote of confidence |
| 09/5/2025 | 07:00 | UK RNS | Genflow Biosciences PLC Share Subscription, Director's Dealing and Update |
| 30/4/2025 | 15:29 | UK RNS | Genflow Biosciences PLC Final Results |
| 14/4/2025 | 07:00 | UK RNS | Genflow Biosciences PLC Launch of AI-Powered Partnership |
| 10/4/2025 | 14:24 | ALNC | IN BRIEF: Genflow launches new ophthalmology development programme |
| 10/4/2025 | 07:00 | UK RNS | Genflow Biosciences PLC Genflow Launches New Development Program |
Genflow Biosciences (GENF) Share Charts1 Year Genflow Biosciences Chart |
|
1 Month Genflow Biosciences Chart |
Intraday Genflow Biosciences Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 22/5/2025 | 09:36 | Genflow Biosciences plc 2022 | 1,607 |
| 14/6/2023 | 18:08 | Old age a thing of the past? | 61 |
| 15/4/2022 | 11:31 | US SEC indicts key shareholder | - |
| 01/2/2022 | 11:45 | Welcome | 3 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 12:28:02 | 0.86 | 39,952 | 344.59 | O |
| 12:10:45 | 0.87 | 50,000 | 432.50 | O |
| 11:28:26 | 0.91 | 40,217 | 366.78 | O |
| 09:16:44 | 0.91 | 31,912 | 291.04 | O |
| 08:05:50 | 0.91 | 54,491 | 497.50 | O |
| Top Posts |
|---|
Posted at 23/5/2025 09:20 by Genflow Biosciences Daily Update Genflow Biosciences Plc is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker GENF. The last closing price for Genflow Biosciences was 0.90p.Genflow Biosciences currently has 349,706,618 shares in issue. The market capitalisation of Genflow Biosciences is £3,147,360. Genflow Biosciences has a price to earnings ratio (PE ratio) of -2.00. This morning GENF shares opened at 0.90p |
Posted at 11/5/2025 19:15 by moneymunch The aim of the seven-year XPrize Healthspan is to develop a way for humans to dramatically rejuvenate muscles, cognition and immune functions, the three systems crucial to healthy ageing.The winning team should be able to restore these three systems by a minimum of 10 – but ideally 20. Given Sirt6's panacea potential across multiple disease targets and XPrize Healthspan criteria, one would have thougt Genflow could be in the running. Gla ;-) Genflow Biosciences (LON:GENF) (OTCQB:GENFF) 1,929 followers 6d 💪 Muscle Loss & #Aging – Can We Stop It? 📉 After age 30, we lose 3-8% of muscle mass per decade, leading to frailty and loss of independence. Current solutions focus on exercise and nutrition, but #biotech could offer more. 🧬 At Genflow Biosciences (LON:GENF) (OTCQB:GENFF), we’re investigating how gene therapy could help maintain #muscle strength and delay #age related decline. A stronger future starts with science. #HealthyAging #Longevity #GENF #GENFF .......... Genflow Biosciences (LON:GENF) (OTCQB:GENFF) 1,929 followers 1w Can We Delay Cognitive Aging? #Neurodegeneration is one of aging’s biggest challenges - memory loss, confusion, and diseases like #Alzheimer’s take a toll on quality of life. Our research at Genflow Biosciences (LON:GENF) (OTCQB:GENFF) focuses on #longevity genes that could help protect brain function, keeping minds sharper for longer. #GENF #GENFF #Aging #BrainFunction ........... SIRT6, a sirtuin protein, plays a complex and multifaceted role in immune functions, acting as both a regulator and an inhibitor of inflammation, and influencing various aspects of immune cell behavior. It impacts immune cell metabolism, T cell differentiation, and the balance of immune cell populations, demonstrating its influence on both innate and adaptive immunity. |
Posted at 09/5/2025 07:04 by moneymunch RNS Number : 9758HGenflow Biosciences PLC 09 May 2025 9 May 2025 Genflow Biosciences plc ("Genflow" or the "Company") Genflow Secures £500,000 via a Subscription of Shares, Director's Dealing and Clinical Progress of Canine Longevity Trial Introduction Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company"), is pleased to announce that it has raised gross proceeds of £500,000 (before expenses) via an allotment to Eric Leire of 62,500,000 new ordinary shares of £0.0003 each ("New Ordinary Shares") at an issue price of 0.8 pence (being the bid price as at close of business on 8 May 2025) (the "Issue Price"). The net proceeds of this fundraise will be used to advance a proof-of-concept trial evaluating the safety and efficacy of our therapeutic candidate in aged dogs, potentially being also a key translational model for age-related conditions in humans. Issuance of the New Ordinary Shares The Company is currently unable to issue and admit the New Ordinary Shares without either the publication of a prospectus approved by the Financial Conduct Authority ("FCA") or relying upon an exemption to the requirement to issue a prospectus. Consequentially, this fundraise involves a subscription by Eric Leire, CEO and director of the Company, for the New Ordinary Shares at the Issue Price pursuant to the employee offer exemption under Article 1(4)(i) and 1(5) (h) of the UK Prospectus Regulation. Following allotment of the New Ordinary Shares, Eric Leire has agreed to direct their issue to an institution, who will immediately sell these New Ordinary Shares at the same Issue Price to a purchaser identified by it (the "Purchaser"). Warrants Concurrent with the purchase of the New Ordinary Shares, the Purchaser will receive warrants from the Company on a one-for-one basis. These warrants will be exercisable for a period of 36 months at an exercise price of 1.5 pence ("Exercise Price"), subject to adjustment in certain circumstances as set out in the warrant instrument including a reset of the Exercise Price if the Company completes a share issuance (or other transaction granting rights to subscribe for equity securities) during the Exercise Period at a price lower than the Exercise Price. Total Voting Rights Application will be made for the 62,500,000 New Ordinary Shares, which will rank pari passu in all respects with the existing Ordinary Shares of the Company, to be admitted to the FCA official list and to trading on the equity shares (transition) category of the Official List maintained by the FCA and to trading on the main market for listed securities of the LSE, which is expected to occur on or around 8.00 a.m. on 15 May 2025 (the "Admission"). Upon Admission, the total number of issued shares and the total number of voting rights in the Company will be 453,547,942. The above figure of 453,547,942 should be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules. Clinical Progress of Canine Longevity Trial Coinciding with the fundraise, Genflow reached a key milestone with the randomization of 24 senior dogs enrolled in its ongoing proof-of-concept clinical trial. Delivered via intravenous injection, the therapy targets cellular energy metabolism and longevity pathways. Genflow and its partners are conducting the study in accordance with the rigorous scientific protocols, leading animal welfare practices, and a committement to innovation. The study is designed to evaluate the potential of Genflow's SIRT6 gene therapy to improve muscle function, reduce biological markers of aging, and support overall vitality in senior dogs, potentially uncovering insights that could help extend the quality of life for humans. An overview can be seen below: · Participants: 24 senior dogs (male and female), aged 10+ years · Design: Randomized, controlled, dose-escalation trial · Endpoints: Safety of the gene therapy, Muscle strength and mass, biological age estimation (via pan-mammelian methylation clocks), and overall health indicators The Company will keep the market informed of future developments as trials proceed. Eric Leire, CEO of Genflow, commented: "This investment, without applying any discount, is a strong vote of confidence in our science and our mission to improve aging through innovative biotechnology. With this support, we are well-positioned to accelerate our research and bring us closer to delivering impactful solutions to patients." |
Posted at 01/5/2025 19:41 by travis walton This is what a pump and dump scammer looks like _night10 - 14 Apr 2025 - 07:23:48 - 18708 of 19893Check out the huge AI RNS at GENF Genflow.I reckon it will 5 bag this week m_night10 - 14 Apr 2025 - 07:11:57 - 1004 of 1190Holy fk look at the #GENF Genflow AI rns!This weeks AI 5 bagger m_night10 - 14 Apr 2025 - 07:11:44 - 697 of 719Holy fk look at the #GENF Genflow AI rns!This weeks AI 5 bagger m_night10 - 14 Apr 2025 - 07:11:30 - 363131 of 363784Holy fk look at the #GENF Genflow AI rns!This weeks AI 5 bagger m_night10 - 14 Apr 2025 - 07:11:17 - 1129 of 1611Holy fk look at the #GENF Genflow AI rns!This weeks AI 5 bagger m_night10 - 14 Apr 2025 - 07:11:06 - 241 of 323Holy fk look at the #GENF Genflow AI rns!This weeks AI 5 bagger m_night10 - 14 Apr 2025 - 07:10:51 - 2234 of 2250Holy fk look at the #GENF Genflow AI rns!This weeks AI 5 bagger |
Posted at 30/4/2025 16:30 by moneymunch Final ResultsChairperson's Report Dear Shareholders, Introduction I am pleased to present my statement as the Chairperson of Genflow Biosciences Plc (GENF) (the "Company"). The Company is a preclinical biotechnology company focused on the development of innovative biological interventions (namely gene therapies) which are aimed at tackling the effects of aging, potentially slowing or halting the aging process and so reducing the incidence of age-related diseases thereby increasing life span. During 2024, the Company made significant progress with its two core research programmes, MASH (Metabolic Dysfunction-Associat Most notably, our MASH study is advancing into the pre-IND phase of preclinical development (a critical stage where companies discuss their product development with the FDA), and we have partnered with Exothera SA for GMP (good Manufacturing Practise) manufacturing of the clinical lot, utilising its state-of-the-art facilities in Belgium. In June 2024, we received positive feedback from the FDA encouraging Genflow to proceed with its plans to identify appropriate animal models through pilot, proof-of-concept studies. This has emboldened us on our journey and provides encouragement that we may receive further positive feedback from the FDA once the Company has submitted a comprehensive briefing package conducted on our lead drug candidate, GF-1002, for the treatment of MASH. An update on the status of each of our research projects has been detailed in the Strategic Report on page 5. On 18 January 2024, we commenced two collaborations with world-class researchers and laboratories which allowed us to receive the support of two non-diluting and non-reimbursable research grants from the Government of Wallonia in Belgium, as follows; · Sarcopenia research program with Revatis SA - focusing on the development of muscle progenitor cells loaded with Genflow's proprietary SIRT6, for the prevention and treatment of sarcopenia, the age-related loss of muscle mass and function. · Exosome-mRNA project with EXO Biologics - which aims to deliver a therapeutic product composed of exosomes encapsulating an AAV or mRNA encoding SIRT6, designed to target MASH and Werner Syndrome. During 2024, the Company has received grant funding totalling €777,281 in respect of 50% these projects, with the further 50% financial support committed in the first half of 2026, subject to spending over the working capital requirements. In 2024, other operating income totalling £320,471 has been recognised in the Consolidated Statement of Comprehensive Income in relation to these grants. Funding In October 2024, we received official confirmation from the Wallonia region of this continued support for our MASH project in the form of €4,026,525 in non-dilutive financial support, subject to the Company meeting certain conditions, which will continue to fund the ongoing development of Genflow's lead gene therapy for the treatment of MASH. The Wallonia region's financial support highlights the growing recognition of Genflow's innovative work in gene therapy. The financial support comprises non-reimbursable research grants and a recoverable advance, repayable to the Wallonia region upon commercialisation. This funding, is expected to cover three years of Genflow's development program for GF-1002, with the first instalment being received as working capital and is receivable subject to Genflow meeting certain capital requirements. Further strengthening the Company's financial position and increasing its institutional investor base, the Company completed a placing and subscription of £715,000 (before expenses) in April 2024. We were privileged to have Premier Miton, a well-known UK institution, participate in this fundraise. The Company completed a further fund raise in March 2025 with a major institution for an equity investment totalling £434,083 (before expenses), in order to accelerate the Company's planned 2025 programs including launching a clinical trial in aged dogs. 2025 During 2025, the Company plans to continue advancing its existing research programs, along with embarking on an exciting clinical trial focused on aged dogs. In early 2025, we commenced a proof-of-concept clinical trial to evaluate the safety and efficacy of our proprietary SIRT6-centenarian gene therapy targeting age-related decline in dogs. In addition to this, we will shortly launch a new development program in ophthalmology, focused on advancing a novel gene therapy which utilizes a specially designed non-viral vector engineered for precise delivery of Genflow's SIRT6 to the eye. The therapy is designed to combat ocular problems including several pathologies of the cornea and glaucoma. |
Posted at 22/4/2025 19:28 by moneymunch Genflow Biosciences (LON:GENF) (OTCQB:GENFF)1,912 followers 5h Check out Genflow Biosciences (LON:GENF) (OTCQB:GENFF) latest presentation! Learn about #GENF's impressive financials, recent milestones in its #SIRT6 studies, and exciting future plans. See it here: #GENF #GENFF #Biotech #MASH #WernerSyndrome #Sarcopenia #Aging |
Posted at 26/3/2025 07:03 by moneymunch RNS Number : 1473CGenflow Biosciences PLC 26 March 2025 26 March 2025 Genflow Biosciences Plc Genflow Secures £434,083 from a Leading Institution and Launches a Gene Therapy Trial in Aged Dogs Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company") the only longevity company listed in Europe, is pleased to announce it has received a binding offer from a major institution for an equity investment totalling £434,083 (before expenses). The investor has applied for 41,341,324 Ordinary Shares of £0.0003 each at a price of 1.05p (the "New Ordinary Shares"). The number of New Ordinary Shares applied for by the subscriber is the maximum number of shares (on a fully diluted basis) available to the Company to issue without the need to produce a Prospectus. These New Ordinary Shares cannot be issued until after 9 April 2025 when the Company's headroom, under the Prospectus Rules, increases. An application will be made to the Main Market of the London Stock Exchange, and admission of the New Ordinary Shares to trading is expected on or around 10 April 2025 ("Admission"). The New Ordinary Shares will, when issued, rank pari passu with the Company's existing Ordinary Shares. Director's Intended Participation Eric Leire, a Director of the Company, intends to invest £50,000 on the same terms as the investment outlined above on the basis that such participation falls under the employee offer exemption under Article 1(4)(i) and 1(5)(h) of the UK Prospectus Regulation, and further, subject to the Company not being in a Closed Period at the time of such investment and the same being subject to the Company's share dealing policy. A further announcement will be made in relation to this in due course. Total Voting Rights For the purpose of the Disclosure Guidance and Transparency Rules, following Admission the enlarged issued share capital of the Company will comprise 391,047,942 ordinary shares. For the avoidance of doubt, this excludes any intended equity participation by Eric Leire. The Company does not hold any shares in treasury. The above figure may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure Guidance and Transparency Rules. Tamara Joseph, Chair of the Company, commented "We are extremely pleased to have been approached by an institution who wishes to support Genflow in its journey in pioneering gene therapies to decelerate the aging process. The use of these proceeds will accelerate the Company's proposed studies and trials in aged dogs, an issue which has attracted a great deal of press coverage, including in recent weeks." Use of Proceeds This investment, combined with previously awarded government grants, will accelerate the Company's planned 2025 programs including launching a clinical trial in aged dogs. Genflow has commenced a proof-of-concept clinical trial to evaluate the safety and efficacy of its proprietary SIRT6-centenarian gene therapy targeting age-related decline in dogs. The Company will treat the dogs for 6 months and assess the safety and efficacy of our therapy for the following 6 months. This is a randomized, controlled trial with 28 dogs aged 10+ years, conducted with the renowned CRO, Syngene. Genflow will compare recipient dogs of intravenous injections of proprietary SIRT6 gene therapy versus untreated control group. Endpoints will include biological age estimation (via GRIM methylation clock), muscle strength, muscle mass, mitochondrial function, coat quality and overall health indicators. "As a devoted dog owner myself, I have a 9-year-old golden retriever, I know firsthand the desire we all share for more happy, healthy years of with our beloved pets," said Dr. Eric Leire, CEO of Genflow. "Our goal is not just to extend their lifespan, but to enhance their quality of life. By targeting biological aging in dogs, we also can unlock groundbreaking insights that could revolutionize both veterinary and human medicine. This research has the potential to reshape the way we approach aging, offering hope for longer, healthier lives for all." Further updates on the progress of the study will be provided in due course |
Posted at 21/2/2025 07:27 by moneymunch Genflow Biosciences (LON:GENF) (OTCQB:GENFF)1,833 followers 19h 🧬 Big things are happening at Genflow Biosciences (LON:GENF) (OTCQB:GENFF)! The European Patent Office has advanced #GENF's exclusive, out-licensed patent for "Variants of #SIRT6 for Use in Preventing and/or Treating Age-Related Diseases." This marks a critical step toward securing market-specific protections across Europe - reinforcing our leadership in longevity focused #biotech. Read the release here: #GENFF #Healthspan #Longevity ............ Genflow Biosciences (LON:GENF) (OTCQB:GENFF) 1,833 followers 18h 🧬 What is #MASH, and why does it matter? Metabolic dysfunction associated steatohepatitis (MASH), formerly known as NASH, is a progressive #LiverDisease caused by fat buildup and #inflammation. It can lead to: 🔹 Fibrosis (scarring of the liver) 🔹 #Cirrhosis (severe liver damage) 🔹 Liver failure or cancer With no approved treatments available, MASH is a growing global health concern. At Genflow Biosciences (LON:GENF) (OTCQB:GENFF), we are working to change that by harnessing the power of the SIRT6 gene, a key longevity regulator involved in DNA repair and metabolic health. Our lead drug candidate, GF-1002, is designed to address MASH by delivering a centenarian variant of #SIRT6 to the liver. We’re pioneering new frontiers in gene therapy to tackle aging related diseases at their root. Stay tuned as we advance - the future of liver health is evolving! 🧬 #GENF #GENFF #Healthspan |
Posted at 12/11/2024 15:23 by moneymunch Genflow Biosciences (LON:GENF) (OTCQB:GENFF)’Genflow Biosciences (LON:GENF) (OTCQB:GENFF) 1,767 followers 1d 🧬 Why Genflow Biosciences (LON:GENF) (OTCQB:GENFF)? 🧬 Genflow Biosciences offers investors a unique opportunity to support a #biotech company revolutionizing the #longevity field. Our innovative #SIRT6 work has led to recent attention, including being named "A Firm to Watch" by The Guardian. Learn more about #Genflow's investment story: #GENF #GENFF #invest #smallcap |
Posted at 22/10/2024 07:08 by moneymunch 22 October 2024Genflow Biosciences Plc Genflow Secures €4 Million Non-Dilutive Financial Support from Wallonia Region for GF-1002 Development Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases is pleased to announce today that it has received official confirmation of €4,026,525 in non-dilutive financial support from the Wallonia region. The funds will support the ongoing development of Genflow's lead gene therapy, GF-1002, for the treatment of Metabolic Associated Steatohepatitis (MASH), a severe and progressive liver disease. The financial support comprises a €1,218,349.44 non-reimbursable research grant, covering 70% of the Company's research costs, and a €2,808,175.92 recoverable advance, repayable to the Wallonia region upon commercialisation GF-1002 for use in treating MASH, funding 55% of the Company's development costs. This funding, when received, is expected to cover three years of Genflow's development program for GF-1002,with the first installment being received as working capital. The Company is committed to securing the necessary funding to cover its share of the project over the next three years. The securing of such funding marks a significant milestone for Genflow and will enable the Company to accelerate the clinical progress of GF-1002, which represents a novel approach to treating MASH, a condition with limited treatment options. The Wallonia region's financial support highlights the growing recognition of Genflow's innovative work in gene therapy. Dr. Eric Leire, CEO of Genflow, commented: "We are delighted to receive this substantial financial backing from the Wallonia region as it is an important validation of our research and development efforts. It will allow us to further the development of GF-1002 and strengthen our position at the forefront of gene therapy innovation for MASH treatment. We would like to sincerely thank the Wallonia region for its support." Further updates on the progress of GF-1002 will be provided in due course. |
Posted at 30/9/2024 07:04 by moneymunch PRESS RELEASE30 September 2024 Genflow Biosciences Plc ("Genflow" or "the Company") HALF YEAR RESULTS Genflow (LSE: GENF) is pleased to announce its half year results for the six-month period ended 30 June 2024. Chairman's Statement It is with pleasure that I take this opportunity to update shareholders of Genflow Biosciences Plc ("Genflow" or the "Company") on the Company's performance during the first six months of 2024. Over the six months to 30 June 2024, the Company has made strides in its principal longevity programs: MASH (Metabolic Dysfunction-Associat In June, we updated shareholders on the momentum created with respect to our pre-clinical programs in MASH, and the guidance expected to be received from the FDA in the future. This guidance, which we anticipate receiving in the future, is expected to come through the FDA's Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT), as a result of the Company submitting a comprehensive briefing package conducted with our lead drug candidate, GF-1002, for the treatment of MASH. In the meantime, the FDA has encouraged Genflow to proceed with its plans to identify appropriate animal models through pilot proof-of-concept ("POC") studies. Specifically, we have established a functional 3-D organoids of liver using cells from Werner patients. This organoid testing helps reduce the need for animal models in our scientific research. Organoids are miniature, lab-grown versions of human organs or tissues that mimic the structure and function of their real counterparts. By using these organoids, we can model human Werner Syndrome and better test response of our SIRT6 based gene therapy in a more human-relevant environment, rather than relying on unreliable animal models. Additionally, we have initiated a feasibility study with a Contract Development Manufacturing Organization (CDMO), Exothera S.A, to assess the ability to produce its future MASH clinical lot in accordance with Good Manufacturing Practices (GMP). We are also in the process of selecting Contract Research Organizations (CROs) to conduct our upcoming dog clinical trial, aimed at studying our simplified Nake DNA version of our Centenarian SIRT6 drug candidate, GF-1004. We will provide updates in relation to our veterinary study in due course. Over the period, we have also been working on two exciting collaborations supported by non-diluting and non-reimbursable research grants from the Government of Wallonia in Belgium, as follows; · Sarcopenia research program with Revatis SA - focusing on the development of muscle progenitor cells which will be loaded with Genflow's proprietary SIRT6 for the prevention and treatment of sarcopenia, the age-related loss of muscle mass and function. Genflow aims to counteract the detrimental effects of aging on muscle tissue with our sarcopenia program, which holds potential for significantly improving the quality of life for older adults affected by muscle loss and weakness. · Exosome-mRNA project with EXO Biologics - which aims to deliver a therapeutic product composed of exosomes encapsulating an AAV or mRNA encoding SIRT6. The exosome therapy will be designed to target liver fibrosis (MASH) and Werner Syndrome, potentially leading to groundbreaking treatments for both diseases. During the period, the Company has received grant funding of totalling €777,281 in respect of these projects, with further financial support committed in the first half of 2025. In addition, Genflow Biosciences SRL, received €350,000 in April 2024, from the regional government of Wallonia - Belgium Service Public de Wallonie, representing the second tranche of this awarded grant recognised in the previous year, 2023. Further strengthening the Company's financial position and increasing its institutional investor base, the Company completed a placing and subscription to which raised £715,000 (before expenses) during the period. We were privileged to have Premier Miton, a well-known UK institution, participate in this fundraise. Financial Overview As of 30 June 2024, the Group had cash reserves of £1,139,859 (31 December 2023: £683,974) which has been derived from equity fundraising of £663,600 (net of expenses) and the receipt of research and development grants of £664,219 (€777,281) and £299,145 (€350,000) The Company remains debt free. Administration expenses for 30 June 2024 totalled £1,316,368 (30 June 2023: £815,477), which primarily consisted of research and development costs of £938,109 (30 June 2023: £415,157), legal and professional fees totalling £90,654 (30 June 2023: £103,366) and Directors' fees of £178,656 (30 June 2023: £178,783). The significant jump in research and development costs for 2024 is in relation to the advancement of testing, which has transitioned to the in vivo stage, which is inherently more costly. Other Comprehensive Income was charged with a translation gain of £8,652 upon converting the Subsidiary's results for the period to GBP. Future On behalf of the Board, I thank you for your continued support. Our commitment to pioneering therapeutic solutions for longevity has been strengthened by the support of our collaborative partners and promising feedback from the FDA during the six-months to 30 June 2024. This encouragement reinforces our commitment to developing effective therapeutic solutions for age-related diseases. We remain focused on our mission to improve healthspan, and I look forward to providing you with further updates as we progress through our work programs, including clinical dog trials. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
.png){kind=logo}
